New data on seralutinib presented at the Pulmonary Vascular Research Institute conference in Rio, January 29-February 1, 2025

Gossamer Bio, Inc. presented clinical and preclinical data related to its investigational drug seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February 1st in Rio de Janeiro, Brazil.

Of particular interest the data on sustained benefit of seralutinib over nearly 1.5 years, and the evidence, from preclinical models, of a synergistic treatment effect from the combination of seralutinib and sotatercept. The latter highlights the potential promise of these complementary mechanisms of action when utilized in combination.

These are the links to the posters related to seralutinib presented at the conference

Preclinical Models Support the Synergistic Potential of Seralutinib and Sotatercept in Treating Pulmonary Arterial Hypertension

Sustained Benefit with Seralutinib Treatment: A Post-Hoc Analysis of the TORREY Open-Label Extension

Sustained Effect of Seralutinib on Circulating Biomarkers in the TORREY Phase 2 Open-Label Extension Study

Read more on the press release issued by Gossamer Bio at this link

For context read our previous articles on seralutinib:

The Phase 3 clinical trial to evaluate the safety and efficacy of oral inhalation of seralutinib for pulmonary arterial hypertension is enrolling

Gossamer Bio announces seralutinib meets primary endpoint in phase 2 TORREY study in pulmonary arterial hypertension, December 6, 2022